Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
64 studies found for:    "Genital Diseases, Female" | Japan
Show Display Options
Rank Status Study
1 Recruiting A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
Condition: Ovarian Cancer
Interventions: Biological: avelumab;   Drug: PLD
2 Recruiting Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasm
Interventions: Other: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel
3 Active, not recruiting Bay98-7196, Dose Finding / POC Study
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: Levonorgestrel;   Drug: Anastrozole + Levonorgestrel (BAY 98-7196);   Drug: Lupron / Leuprolide acetate
4 Completed A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
Condition: Endometriosis
Interventions: Drug: ASP1707;   Drug: Placebo;   Drug: Leuprorelin acetate
5 Completed Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis
Condition: Endometriosis
Interventions: Drug: EE20/DRSP(BAY86-5300);   Drug: Placebo;   Drug: Dienogest
6 Recruiting Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: Paclitaxel(intravenous) + Carboplatin(intravenous);   Drug: Paclitaxel(intravenous) + Carboplatin(intraperitoneal)
7 Completed Efficacy and Safety of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
8 Completed A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
Condition: Endometriosis
Interventions: Drug: Placebo;   Drug: TAK-385;   Drug: Leuprorelin acetate
9 Completed
Has Results
Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan
Condition: Pelvic Inflammatory Disease
Intervention: Drug: Azithromycin
10 Completed Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
11 Completed Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)
Condition: Uterine Cervical Neoplasms
Interventions: Drug: chemotherapy: Paclitaxel/Cisplatin;   Drug: chemotherapy: Paclitaxel/Carboplatin
12 Completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Conditions: Ovarian Clear Cell Cystadenocarcinoma;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Drug: Temsirolimus
13 Recruiting CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance;   Atypical Endometrial Hyperplasia;   Human Papillomavirus Infection;   Stage 0 Cervical Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
14 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
15 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
16 Active, not recruiting
Has Results
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Neoplasms, Ovarian
Interventions: Drug: Pazopanib;   Drug: Placebo
17 Active, not recruiting Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Conditions: Adult Type Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Steroid Cell Tumor
Intervention: Drug: Paclitaxel
18 Recruiting Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
Condition: Ovarian Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Drug: Avelumab
19 Unknown  Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
20 Active, not recruiting TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: Paclitaxel;   Drug: AMG 386 Placebo;   Drug: Carboplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years